FDA Oncology/X
Jun 10, 2025, 14:52
Camilla Zimmermann: Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults with Cancer
Camilla Zimmermann, Head of the Division of Palliative Care at the Princess Margaret Cancer Centre, posted on X:
“Urgent need for updated guidelines on Systemic Anticancer Therapy use at End of Life: Our study of 68,000+ patients found use of novel SACT at EOL, including immunotherapy, was associated with indicators of poor-quality.”
Title: Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer
Authors: Javaid Iqbal, Rahim Moineddin, Kieran L. Quinn, Christopher M. Booth, Craig C. Earle, Stephanie Lheureux, Robert Grant, Jenny Lau, Lisa W. Le, Peter Tanuseputro, James Downar, Gary Rodin, Hsien Seow, Jillian Tsai, Robert A. Fowler, Breffni Hannon, Monika K. Krzyzanowska, Camilla Zimmermann
Read The Full Article at Journal of Clinical Oncology.
More posts featuring Cancer.
anticancer therapy
Breffni Hannon
Camilla Zimmermann
cancer
Christopher M. Booth
Craig C. Earle
Gary Rodin
Hsien Seow
James Downar
Javaid Iqbal
Jenny Lau
Jillian Tsai
Kieran L. Quinn
Lisa W. Le
Monika K. Krzyzanowska
OncoDaily
Oncology
Peter Tanuseputro
Rahim Moineddin
Robert A. Fowler
Robert Grant
Stephanie Lheureux
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 10, 2025, 14:44
Jun 10, 2025, 14:14
Jun 10, 2025, 12:19
Jun 10, 2025, 12:16